HUMA — Humacyte, Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1818382 ·
Last close
$0.50
Market Cap
$139.18M
52W High
$1.52
52W Low
$0.34
ADV30
6,141,273
Next earnings
2026-11-10
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 406,000 -825,000 -26,996,000 -36,802,000 138,087,000 79,903,000 106,826,000
Mar 2026 495,000 -1,543,000 -28,935,000 -17,619,000 110,557,000 48,539,000 98,933,000
Dec 2025 467,000 -8,615,000 -30,836,000 -24,804,000 116,366,000 50,497,000 113,257,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-88,263,000
Investing CF
$-318,000
Financing CF
$133,616,000
CapEx
$-367,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.42
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-796,807,000
Inventory
$5,611,000
Receivables
$811,000
ST Investments
—
EBIT TTM
$-84,708,000
Pretax Income TTM
$-94,763,000
Interest Exp TTM
$10,055,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,396,000
EBITDA
$-102,497,000
Free Cash Flow
$-56,109,624
Enterprise Value
$157,081,456
Total Cash
$64,523,000
Total Debt
$66,482,000
Shares Out
277,798,105
Trailing EPS
$-0.45
Book Value
$0.07
ROE
-1423.6%
ROA
-63.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,038,000 -108,137,000 -40,833,000 116,366,000 113,257,000 3,109,000 -105,042,000
Dec 2024 0 -114,398,000 -148,701,000 137,872,000 190,541,000 -52,669,000 -98,122,000
Dec 2023 0 -100,047,000 -110,776,000 128,223,000 114,677,000 13,546,000 -73,305,000
Dec 2022 0 -84,578,000 -11,965,000 204,302,000 87,374,000 116,928,000 -71,129,000

TTM Snapshot

Revenues TTM
$2,121,000
NetIncome TTM
$-96,735,000
OpCashFlow TTM
—
Assets (Latest)
$138,087,000
Forward EPS
$-0.25

Max Pain — expiry 2029-01-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $1.00 · spot: $0.50 · call volume: 52 · put volume: 280
Expected Move to 2029-01-19: ±$0.65 (130.00%) — implied range $-0.15 – $1.15 · ATM straddle on $0.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
TARA Protara Therapeutics, Inc. $137.10M $2.32 —
STRO SUTRO BIOPHARMA, INC. $148.08M $8.92 —
IPHA Innate Pharma SA $148.56M $1.33 —
IVVD Invivyd, Inc. $151.09M $0.51 —
FATE FATE THERAPEUTICS INC $124.00M $1.02 —

News headlines (Yahoo Finance, 1h cache)

Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
2026-11-16 13:00 · Yahoo
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
2026-11-11 13:00 · Yahoo
Humacyte (HUMA) Q3 2026 Earnings Call Transcript
2026-11-10 22:04 · Yahoo
Humacyte, Inc. Q3 2026 Earnings Call Summary
2026-11-10 21:59 · Yahoo
Humacyte Q3 Earnings Call Highlights
2026-11-10 17:15 · Yahoo
Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates
2026-11-10 12:15 · Yahoo
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
2026-11-10 12:00 · Yahoo
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
2026-11-09 13:00 · Yahoo
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-11-05 22:00 · Yahoo
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
2026-11-03 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.